Page 2 - New Technologies News Today

English ...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive

Forum of Kazakh-Language Content Creators in Astana Explores Emerging Trends and Risks

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support BioNTech

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support...

In the ever-evolving Irish business landscape, small businesses are an integral part of the national economic framework. Entrepreneurship thrives on the Emerald Isle, buoyed by a spirit of innovation and resilience despite the array of challenges it faces. The Irish government recognises the crucial role played by these enterprises and, as a result, has rolled out tailored measures to bolster their growth

MAINZ, Germany, May 21, 2024 - BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the

Investegate announcements from BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024